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https://doi.org/10.1016/j.stemcr.2020.03.011SUMMARYThe blood-brain barrier (BBB) presents a barrier for circulating factors, but simultaneously challenges drug delivery. How the BBB is altered
in Alzheimer disease (AD) is not fully understood. To facilitate this analysis, we derived brain endothelial cells (iBECs) from human
induced pluripotent stem cells (hiPSCs) of several patients carrying the familial AD PSEN1 mutation. We demonstrate that, compared
with isogenic PSEN1 corrected and control iBECs, AD-iBECs exhibit altered tight and adherens junction protein expression as well as
efflux properties. Furthermore, by applying focused ultrasound (FUS) that transiently opens the BBB and achieves multiple therapeutic
effects in ADmousemodels, we found an altered permeability to 3–5 kDa dextran as amodel cargo and the amyloid-b (Ab) peptide in AD-
iBECs compared with control iBECs. This presents human-derived in vitromodels of the BBB as a valuable tool to understand its role and
properties in a disease context, with possible implications for drug delivery.INTRODUCTION
Treatment of neurodegenerative diseases is challenged by
limited passage of therapeutic drugs across the blood-brain
barrier (BBB) to the brain (Pandit et al., 2019a; Sweeney
et al., 2018). The BBB lines the walls of brain microvessels
and is critical to prevent entry of toxic molecules and facil-
itate uptake of nutrients (Zenaro et al., 2017). The func-
tional BBB or neurovascular unit is formed by brain endo-
thelial cells (BECs), pericytes, astrocytes, and neurons,
with BEC-expressed tight junctions inhibiting the entry
of unwanted molecules into the central nervous system
(CNS) (Zenaro et al., 2017). BBB-specific tight junction
proteins (TJPs) and adherens junction proteins include
occludin, claudins (claudin-3 and claudin-5), ZO-1, and
VE-cadherin (Li et al., 2018; Sweeney et al., 2018). BEC-ex-
pressed efflux transporters, such as P-glycoprotein (P-gp),
multidrug resistance proteins (MRPs), and breast cancer
resistance protein (BCRP) actively pump molecules back
into the blood (Qosa et al., 2015). Uptake transporters,
such as glucose transporter 1 (GLUT-1), ensure the uptake
of vital nutrients into the CNS (Devraj et al., 2011).
Several neurodegenerative diseases, including Alzheimer
disease (AD), have been claimed to be associated with an
abnormal BBB (reviewed in Sweeney et al., 2018). AD is a
complex disorder characterized by amyloid-b (Ab) plaques924 Stem Cell Reports j Vol. 14 j 924–939 j May 12, 2020 j ª 2020 The Auth
This is an open access article under the CC BY-NC-ND license (http://creativand tau-containing neurofibrillary tangles, leading to a
gradual decline of cognition (Polanco et al., 2018). Thema-
jority of AD cases are sporadic (late onset) of unknown eti-
ology, with less than 1% of familial AD (FAD) cases of
known genetic cause and early onset (Ryan et al., 2016).
Multiple FADmutations occur in genes encoding the amy-
loid precursor protein (APP), presenilin-1 (PSEN1), and pre-
senilin-2 (PSEN2) (Ryan et al., 2016). Currently, there is no
cure for AD and therapeutic development is slowed by poor
delivery of compounds across the BBB (Frozza et al., 2018;
Pandit et al., 2019a; Sweeney et al., 2018).
There are multiple changes to the BBB in AD, indicated
by the presence of blood-borne substances and circulating
leukocytes in the CNS (Hultman et al., 2013; Nelson et al.,
2016; Zenaro et al., 2015). BEC and pericyte degeneration,
and cerebrovascular pathology have also been described in
AD patients and mouse models (reviewed in Gama Sosa
et al., 2010; Montagne et al., 2017; Sweeney et al., 2018).
Reduced BBB integrity is associated with neuroinflamma-
tion, neuronal injury, oxidative stress, and faulty clearance
of Ab, as well as altering uptake of therapeutics (reviewed in
Sweeney et al., 2018). However, there is also a recent study
claiming no differences in BBB permeability in human AD
and in AD mouse models (Bien-Ly et al., 2015), high-
lighting the lack of understanding of BBB-specific changes
in AD and what their impact is on drug delivery.or(s).
ecommons.org/licenses/by-nc-nd/4.0/).
(legend on next page)
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Although a disrupted BBB is considered an opportunity
tomore easily deliver drugs into the brain, the altered phys-
iological conditions in the AD-BBB can hinder drug deliv-
ery by diffusion (Sweeney et al., 2018). This reinforces the
importance of establishing AD-specific models of the hu-
man BBB to understand its contribution to AD pathogen-
esis and drug delivery. As a promising approach, BECs
(iBECs) have been generated from human induced plurip-
otent stem cells (hiPSCs) (Lippmann et al., 2014). hiPSC-
derived iBECs express key proteins of BECs, demonstrate
high barrier integrity and exhibit efflux transporter activity
characteristic of the BBB in vivo (Lippmann et al., 2014).
Focused ultrasound (FUS) is a technique that uses acous-
tic energy, together with gas-filled microbubbles (MBs),
traditionally used as ultrasound contrast agents, to tran-
siently open the BBB, potentially allowing for enhanced
drug delivery (Leinenga et al., 2016). Opening of the BBB
is achieved in part through an interaction between MBs
and sound waves leading to loosening of tight junctions
between BECs (Sheikov et al., 2004). Ultrasound has been
used to facilitate delivery of an anti-Ab antibody to reduce
plaque burden (Jordao et al., 2010) and a tau-specific anti-
body fragment to reduce pathological tau and improve
associated behaviors (Nisbet et al., 2017). Ultrasound alone
has been shown to open the BBB in mice with Ab pathol-
ogy, resulting in reduction of plaque burden and restora-
tion of memory functions, without the need for additional
therapeutic agents (Leinenga andGo¨tz, 2015). Similarly, ul-
trasound alone can reduce tau pathology and associated
motor impairments (Pandit et al., 2019b). These results
strongly support the use of low-intensity FUS as a potential
therapeutic modality for AD; however, the effects of FUS in
a human BBB disease model remain unexplored.
Here, we used hiPSCs derived from FAD patients with a
PSEN1 exon 9 deletion (Oksanen et al., 2017) along with
isogenic PSEN1-corrected as well as healthy controls to
study AD-specific differences in human BECs, previously
not described in the literature. We also investigated the po-
tential of human iBECs to model the effects of FUS on BBB
opening. Our results identify key phenotypical differences
between AD- and control (ctrl)-iBECs and demonstrate
the differential effects of FUS on BBB opening in AD- and
ctrl-iBECs.Figure 1. Differentiation of hiPSCs into iBECs
(A) Phase-contrast images of iBECs derived from control (HDFa), isoge
hiPSCs (203 magnification). Scale bar, 50 mm.
(B) Relative expression of mRNA for occludin, VE-cadherin, and claudi
undifferentiated hiPSCs (HDFa: n = 1 line, isogenic COR; n = 2 lines,
(C) Trans-endothelial electrical resistance (TEER) in HDFa-, isogenic C
n = 2 lines, AD: n = 3 lines, 18 technical replicates from n = 3 indepe
Data are presented as mean ± SEM. Statistical analysis between two
groups using one-way ANOVA, *p < 0.05, ***p < 0.001, ****p < 0.00
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Ctrl- and AD-iPSCs Readily Differentiate into iBECs
iBECs were differentiated from three FAD iPSC lines car-
rying the PSEN1 DE9 mutation (AD-iBECs), two isogenic
control iPSC lines where the PSEN1mutation had been cor-
rected (isogenic COR-iBEC) (Oksanen et al., 2017), and one
unrelated control iPSC line generated from human dermal
fibroblasts (HDFa-iBEC). iBEC differentiation was achieved
using previously established protocols with somemodifica-
tions (Lippmann et al., 2014; Stebbins et al., 2016; Qian
et al., 2017). Following purification on plates coated with
collagen IV and fibronectin, all lines displayed endothelial
cell morphology, indicated by a cobblestone-like appear-
ance (Figures 1A and 2A). Compared with undifferentiated
hiPSCs, iBECs generated from all lines expressed higher
levels of endothelial cell and BBB TJP marker genes for oc-
cludin, VE-cadherin, and claudin-5 (Figure 1B). To confirm
the integrity of the iBECmonolayer, the cells were cultured
on Transwell inserts and the trans-endothelial electrical
resistance (TEER) was measured. The mean TEER across
the iBEC lines reflected levels previously published for
iBECs (Lippmann et al., 2014): HDFa-iBEC 4,000 U/cm2;
AD-iBEC 2,900 U/cm2; and isogenic COR-iBEC 4,100 U/
cm2. AD-iBECs exhibited a lower TEER compared with
HDFa- and isogenic COR-iBECs (Figures 1C, and S2C).
TheHDFa- and the two isogenic COR-iBECs showed similar
properties. To streamline the subsequent analyses of
phenotypical differences, we combined and averaged the
data from these three control cell lines and termed them
‘‘combined iBEC’’ (meaning combined control iBECs).
AD-iBECs Express Altered mRNA Levels of TJPs
Compared with Combined Ctrl-iBECs
With both tight and adherens junctions playing a central
role in BBB integrity, we examined and compared their
expression between the two experimental groups. Immu-
nofluorescence for occludin and claudin-5, which were
ubiquitously expressed in all iBEC lines, displayed distinct
localization to cell borders, confirming iBEC specification
(Figures 2A and S2). We then compared levels of mRNA en-
coding BBB-specific TJP and adherens junction proteins be-
tween the combined ctrl-iBECs and AD-iBECs (Figure 2B).nic PSEN1-corrected control (isogenic COR), and PSEN1 mutant AD
n-5 in HDFa-, isogenic COR-, and AD-iBECs shown as fold change to
AD: n = 3 lines, 6 independent replicates).
OR-, and AD-iBECs shown as U/cm2 (ctrl: n = 1 line, isogenic COR;
ndent experiments).
groups was performed using Student’s t test and between multiple
01.
(legend on next page)
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mRNA levels of the occludin gene did not differ between
combined ctrl- and AD-iBECs, although a slightly increased
expression (fold change 1.2, p = 0.055) was identified in
AD-iBECs compared with combined ctrl-iBECs (Figure 2B).
mRNA for adherens junction protein VE-cadherin was ex-
pressed at a lower level in AD-iBECs compared with com-
bined ctrl-iBECs (Figure 2B). The opposite was seen for
claudin-3 and claudin-5 mRNA, which were more highly
expressed inAD-iBECs comparedwith combined ctrl-iBECs
(Figure 2B). ZO-1, which acts as a TJ scaffolding protein was
not differentially expressed, although it demonstrated
slightly increased expression (fold change 1.3, p = 0.06)
in AD-iBECs (Figure 2B). These results demonstrate com-
plex effects of PSEN1 mutation on TJP mRNA expression.
AD-iBECs Exhibit Reduced BBB Transporter
Expression and Increased Activity Compared with
Combined Ctrl-iBECs
Uptake and efflux transporters play a key role in nutrient
uptake of the brain and in expelling unwanted molecules
back to the blood, respectively (Devraj et al., 2011; Qosa
et al., 2015). We therefore analyzed transporter expression
and activity in ctrl- and AD-iBECs. GLUT-1 (responsible for
glucose uptake), was found to be ubiquitously expressed in
the plasma membrane in HDFa-, isogenic COR-, and AD-
iBECs (Figures 3A and S3) and did not demonstrate differ-
ential expression between the iBEC lines at themRNA level
(Figure 3B). Interestingly, mRNA levels of the efflux trans-
porter P-GP were lower in AD-iBECs when compared with
combined ctrl-iBECs (Figure 3C). However, this did not
correlate with significantly altered P-gp-dependent accu-
mulation of rhodamine 123 in AD-iBECs, although a trend
toward increased accumulation was observed (Figure 3D)
(see Supplemental Information for rhodamine assay).
This may reflect differences between gene and protein
levels. Intriguingly, mRNA levels of the efflux transporters
MRP1, MRP2, and BCRP were all higher in AD-iBECs
compared with combined ctrl-iBECs (Figure 3E). How this
relates to transporter activity remains to be investigated.
FUS Transiently Opens the iBEC Monolayer with AD-
iBECs Demonstrating Differential Opening Compared
with Controls
FUS is an innovative technology, and in conjunction with
gas-filledMBs has the potential to transiently open the BBBFigure 2. AD-iBECs Express Altered Levels of TJP Genes Compared
(A) Representative immunofluorescence images in HDFa-, isogenic C
magnification, Hoechst counterstain). Scale bar, 50 mm.
(B) Relative expression of mRNA for occludin, VE-cadherin, claudin
combined)- and AD-iBECs shown as fold change to combined ctrl-iBE
Data are presented as mean ± SEM. Statistical analysis was performed
also Figure S2.
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que load in AD models (Leinenga and Go¨tz, 2015). We
explored the possibility to model the effects of FUS on
the BBB in vitro using AD-iBECs. In these experiments,
two AD-iBEC lines and the corresponding isogenic COR-
iBEC lines (corrected) were used. Conditions included
untreated (UT), ultrasound only (US), MB only, and ultra-
sound plus MBs (US + MB). Of note, MBs alone are consid-
ered to be biologically inert, whereasUS on its own is a pres-
sure wave that can have potential bio-effects (Leinenga
et al., 2016). Cells were analyzed both immediately and
24 h after ultrasound treatment of the expression of clau-
din-5 and occludin, changes to TEER, and permeability to
fluorescently conjugated dextran and Ab.
Immediately after treatment with US at 0.3 MPa peak
rarefactional pressure (120 s), the isogenic corrected
(COR)- and AD-iBEC monolayer was intact in the UT
only and MB conditions, with several small cell-free
patches present in the iBEC monolayer after US (Figures
4A and S4A). Following US + MB treatment, a clear disrup-
tion of the iBEC monolayer was evident in both isogenic
COR- and AD-iBECs, indicated by the presence of clear
cell-free patches in the cellular monolayer (Figures 4A
and S4A). Intriguingly, the cell-free patches within AD-
iBEC cultures were more defined and covered a smaller
area than in the monolayer of isogenic COR-iBECs (Figures
4A, S4A and S4B). To investigate the functional effects of
ultrasound treatment on monolayer integrity, we also
measured TEER after FUS treatment on iBECs cultured in
Transwells (Figures 4C and S4C). These measurements
confirmed that US + MB reduced barrier integrity, with
both isogenic COR- and AD-iBECs demonstrating
decreased TEER in the US + MB condition (isogenic COR:
fold change 0.65; AD: fold change 0.68) compared with
UT, with no difference observed in the reduction of TEER
between the lines (Figure 4C). Although no disruption of
the iBEC monolayer was evident in the MB condition,
reduced TEER was also identified in this condition
compared with UT in isogenic COR-iBECs; however,
TEER remained lower in the US + MB condition compared
with MB (Figure S4C).
To determine if changes in TEER were associated with
US + MB effect on cell-cell barrier integrity or from the
appearance of cell-free spaces, we repeated the treatments
at a lower rarefactional pressure of 0.15 MPa (120 s). Atwith Ctrl-iBECs
OR-, and AD-iBECs of occludin (green) and claudin-5 (red) (203
-3, claudin-5, and ZO-1 in combined ctrl (HDFa and isogenic COR
Cs (ctrl: n = 3 lines, AD: n = 3 lines, six independent replicates).
using Student’s t test, *p < 0.05, **p < 0.01, ****p < 0.0001. See
Figure 3. AD-iBECs Exhibit Altered Expression and Function of Efflux Transporters
(A) Representative immunofluorescence images in control HDFa-, isogenic COR-, and AD-iBECs of GLUT-1 (red) (203 magnification,
Hoechst counterstain). Scale bar, 50 mm.
(B and C) Relative gene expression of (B) GLUT-1 and (C) P-GP in combined ctrl- and AD-iBECs shown as fold change to combined ctrl-iBECs
(HDFa and isogenic COR combined) (ctrl: n = 3 lines, AD: n = 3 lines, 6 independent replicates).
(D) P-gp activity measured by rhodamine 123 uptake in UT- and cyclosporin A (CsA)-inhibited combined ctrl- and AD-iBECs. Graphs display
fold change in fluorescence compared with untreated condition (ctrl: n = 3 lines, AD: n = 3 lines, 7 technical replicates).
(E) Relative gene expression of MRP1, MRP2, and BCRP in combined ctrl- and AD-iBECs shown as fold change to ctrl-iBECs (ctrl: n = 3 lines,
AD: n = 3 lines, 6 independent replicates).
Data are presented as mean ± SEM. Statistical analysis was performed using Student’s t test or ANOVA (D), *p < 0.05, **p < 0.01, ***p <
0.001, ****p < 0.0001. See also Figure S3.
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this setting, no visible changes (cell-free spaces) were
observed in any culture (Figure 4B). This lower US setting,
however, induced the same reduction in TEER in both
isogenic COR-iBECs and AD-iBECs as observed at 0.3 MPa
(Figure 4D compared with Figure 4C). This was consistent
with the observation that the higher setting (0.3 MPa)
did not appear to adversely affect cell health. To confirm
this, we performed an MTT assay for cell health, which
revealed no significant change to cell viability or numbers
after treatment with either 0.3 or 0.15 MPa US + MB (Fig-
ure 4E) and also found that RNA levels of AD-iBECs did
not differ after UT and US + MB treatment.
Importantly, 24 h after US + MB treatment at 0.3 MPa
the isogenic COR- and AD-iBEC monolayers demon-
strated full recovery indicated by the absence of cell-free
patches when stained for claudin-5 and occludin (Fig-
ure 5A). This was supported by TEER measurements per-
formed 24 h after treatment, which demonstrated a slight
increase in TEER in the US + MB condition compared with
UT condition in both isogenic COR- and AD-iBECs and no
difference in TEER between UT and other conditions (Fig-
ures 5B and S4C). Analysis of the intensity of claudin-5
and occludin staining immediately and 24 h after US +
MB treatment confirmed higher claudin-5 expression in
AD-iBECs compared with isogenic COR, with the AD-
iBEC US + MB condition also demonstrating higher
claudin-5 expression compared with the isogenic COR-
iBEC US + MB condition 24 h after treatment (Figure 5C).
The intensity of occludin was shown to be higher after
US + MB in both iBEC lines at the immediate time point,
likely indicating differential localization or clustering of
this protein (Figure 5C). Higher occludin intensity was
also observed in AD-iBEC US + MB condition compared
with the isogenic corrected control US + MB condition
24 h after treatment (Figure 5C).
FUS Causes Changes in TJP mRNA Expression in
AD-iBECs
We then measured the relative expression levels of the TJP
genes immediately and 24 h after FUS to understand the ef-
fect of FUS on TJP expression.When analyzed immediatelyFigure 4. FUS in the Presence of Microbubbles Disrupts AD-iBEC
(A and B) Representative immunofluorescence images of claudin-5 (r
exposed to ultrasound (A, 0.3 MPa; B, 0.15 MPa) and stained immed
cation, DAPI counterstain). Scale bar, 100 mm,
(C) TEER (U/cm2) in isogenic COR- and AD-iBECs in UT and US + MB con
to UT (n = 6 from two independent experiments with two isogenic pa
(D) TEER (U/cm2) in isogenic COR- and AD-iBECs in UT and US + MB
change to UT (n = 6 from two independent experiments with two iso
(E) MTT cytotoxicity assay on UT- and US + MB-treated iBECs at 0.3 a
Data are presented as mean ± SEM. Statistical analysis between two
groups using one-way ANOVA, *p < 0.05, **p < 0.01, ****p < 0.0001(10 s) after treatment (0.3MPa condition), occludin, clau-
din-5, and ZO-1 mRNAs were downregulated in AD-iBECs
after US +MB compared with the UTcondition (Figure 6A).
In isogenic COR-iBECs, only ZO-1 demonstrated decreased
expression after US + MB compared with UT (Figure 6A).
VE-cadherin mRNA, which was expressed at a lower level
in AD-iBECs compared with isogenic COR-iBECs, demon-
strated an increase in AD-iBECs after US + MB treatment
compared with UT (Figure 6A).
Twenty-four hours after US + MB treatment (0.3 MPa),
AD-iBECs continued to demonstrate downregulated occlu-
din, claudin-5, and ZO-1 mRNA expression compare with
UT (Figure 6B). Consistent with the immediate time point,
AD-iBECUTcells continued to express higher levels of clau-
din-5 and ZO-1 mRNA and lower levels of VE-cadherin
mRNA compared with isogenic COR-iBECs (Figure 6B). In
isogenic COR-iBECs, mRNA for VE-cadherin was upregu-
lated in the US + MB condition compared with UT with
an elevated trend in occludin (fold change 1.1) and clau-
din-5mRNAexpression (fold change 1.3) (Figure 6B). These
results suggest that TJP gene expression does not recover at
a similar rate in AD-iBECs compared with isogenic COR-
iBECs after FUS at 0.3 MPa. Given the complexity of TJP
mRNA changes in response to FUS, future studies should
investigate this in more detail at different pressure settings
and time points post-treatment.
FUS Increases the Permeability of the AD-iBEC
Monolayer Demonstrating Reduced Recovery in
Permeability
Finally, we examined the ability of FUS to increase the
permeability of the iBEC monolayer by examining the
passage of the fluorescently conjugated carrier molecule
dextran (sized 3–5 kDa) and Ab (1–42) (sized 4 kDa, added
without pre-aggregation) through the iBEC monolayer
(Figure 7A). The isogenic COR-iBEC UT condition was
used as a baseline to which all the treatment conditions
in both iBEC lines were compared. Immediately after
treatment (0.3 MPa), consistent with the TEER mea-
surements, the permeability to dextran was increased in
the US + MB condition (fold change 2.5) in isogenicMonolayer Differently Compared with Ctrl-iBECs
ed) and occludin (green) co-stained in isogenic COR- and AD-iBECs
iately (Imm.) after treatment (UT, MB, US, US + MB, 203 magnifi-
ditions (0.3 MPa) immediately after treatment shown as fold change
irs).
conditions (0.15 MPa) immediately after treatment shown as fold
genic pairs).
nd 0.15 MPa rarefactional pressure (Imm.).
groups was performed using Student’s t test and between multiple
. See also Figure S4.
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COR-iBECs with an increased trend also observed in AD-
iBEC US + MB condition (fold change 1.7) (Figure 7B).
No significant difference in permeability was identified
between the US + MB conditions in isogenic COR- and
AD-iBECs (Figure 7B). We also found increased perme-
ability of both isogenic COR-iBECs and AD-iBECs with
the lower rarefactional pressure (0.15 MPa) US + MB treat-
ment (Figure S5D).
Twenty-four hours after ultrasound treatment (0.3 MPa)
the same iBEC cultures were exposed to dextran again,
with no difference in dextran leakage observed between
UT and US + MB conditions in isogenic COR-iBECs, sup-
porting recovery of barrier integrity (Figure 7C). In
contrast, 24 h after treatment, AD-iBECs demonstrated a
persisting increased permeability to dextran in the US +
MB condition compared with UT (Figure 7C). Dextran
permeability in the AD-iBEC US + MB condition was
also higher when compared with isogenic COR-iBEC UT
and US + MB conditions (Figure 7C). As above, the
same effect was observed at the lower pressure of
0.15 MPa (Figure S5E), indicating that increased perme-
ability to dextran in AD-iBECs 24 h after treatment was
not associated with the formation of cell-free spaces that
were observed immediately after treatment at the higher
pressure of 0.3 MPa.
Next, fluorescently conjugated Ab1-42 (Ab) was added to
iBEC cultures immediately after 0.3 MPa ultrasound treat-
ment and incubated for 24 h, after which the media in
the top and bottom chamber of the Transwell were
analyzed for fluorescence. In isogenic COR-iBECs, no dif-
ference in Ab leakage was identified after US + MB
compared with the UT condition (Figure 7D). Intriguingly,
AD-iBEC cultures demonstrated a strong increase in Ab
permeability after US + MB compared with the UT
condition (Figure 7D). Increased Ab leakage through the
AD-iBECmonolayer after US +MB treatment was also iden-
tifiedwhen comparedwith isogenic COR-iBECUTandUS +
MB conditions (Figure 7D). These results correlated with
the permeability to dextran at 24 h and suggested impaired
recovery of the AD-iBEC monolayer after US + MB treat-
ment. US and MB alone conditions did not induce perme-
ability to Ab (Figure S5).Figure 5. iBEC Monolayer Recovers 24 h after Ultrasound Treatme
(A) Representative immunofluorescence images of claudin-5 (red) and
exposed to US + MB and stained 24 h after treatment (203 magnific
(B) TEER (U/cm2) in isogenic COR- and AD-iBECs in UT and US + MB co
(n = 6 from two independent experiments with two isogenic pairs). Da
using Student’s t test, *p < 0.05.
(C) Mean signal intensity of claudin-5 and occludin immediately and 2
fold change to isogenic corrected UT condition (n = 9 from three ind
Data are presented as mean ± SEM. Statistical analysis was performed u
0.0001. Only relevant differences are shown. See also Figure S4.DISCUSSION
The BBB protects the brain from toxins and infectious
agents, although even under physiological conditions
there is an inherent ‘‘leakiness’’ allowing limited passage
of some large molecules (Golde, 2014). Perturbations to
the BBBhave been reported in AD, but how this contributes
to disease remains largely unknown (Sweeney et al., 2018).
Advances in iPSC technology to generate human BECs pro-
vide new opportunities to explore BBB pathology in AD
(Qian et al., 2017). Here, we established a model of the
AD-BBB, by generating iBECs from FAD patient-derived
hiPSCs harboring the PSEN1 DE9 mutation, correcting
the mutation to generate isogenic controls, and further,
including cells from healthy individuals. We found that
AD-iBECs exhibited differences both at the expression
and functional level compared with ctrl-iBECs, reinforcing
the notion of disease-specific impairments at the BBB. We
also examined the cell response to therapeutic ultrasound
with our results showing the ability of FUS together with
MBs to open the iBEC tight junctions as a potential means
for enhanced drug delivery across the BBB. Importantly,
AD- and isogenic COR-iBECs responded differently to
FUS, highlighting differences in the PSEN1 mutant BBB
and the importance of disease-specific models to develop
drug delivery. Although iBECs can provide information
on disease-specific differences at a cell-type-specific level,
in the complete BBB, iBECs interact with astrocytes and
pericytes, which may modulate how the disease mutation
influences BBB function.
BBB breakdown in AD has been broadly reported (re-
viewed in Montagne et al., 2017) with our results support-
ing reduced BBB integrity in FAD for small molecules, with
PSEN1mutant AD-iBECs exhibiting lower TEER compared
with ctrl-iBECs. Interestingly, our analysis of TJP expres-
sion identified key differences between AD- and ctrl-iBECs,
with both up- and downregulated genes, suggesting an
altered brain endothelial phenotype in PSEN1 mutation
AD. It is possible that these changes are specific to PSEN1
mutations and are not represented in other forms (i.e.,
late-onset sporadic) of AD. Our central findings are that
in PSEN1mutant AD- compared with combined ctrl-iBECs,nt
occludin (green) along with co-stain in isogenic COR- and AD-iBECs
ation, DAPI counterstain). Scale bar, 100 mm.
nditions 24 h after treatment shown as fold change to UT condition
ta are presented as mean ± SEM. Statistical analysis was performed
4 h after US + MB treatment in isogenic COR- and AD-iBECs shown as
ependent experiments with two isogenic pairs).
sing two-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001, ****p <
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Figure 7. FUS Increases the Permeability
of the iBEC Monolayer to 3–5-kDa Dextran
and Ab with AD-iBECs Demonstrating
Sustained Permeability 24 h after Treat-
ment
(A–C) (A) Assay of fluorescent dextran and
Ab leakage across iBECs in Transwells.
Fluorescent dextran (3–5 kDa) leakage in
isogenic COR- and AD-iBECs (B) immediately
and (C) 24 h after US + MB treatment
(0.3 MPa).
(D) Fluorescently conjugated Ab leakage in
isogenic COR- and AD-iBECs 24 h after US +
MB treatment (0.3 MPa). Results shown as
fold change to isogenic COR-iBEC UT con-
dition (n = 3 independent replicates with
two isogenic pairs).
Data are presented as mean ± SEM. Statis-
tical analysis was performed using two-way
ANOVA, **p < 0.01, ***p < 0.001, ****p <
0.0001. Only relevant differences are
shown. See also Figure S5.mRNA levels for VE-cadherin were reduced, and claudin-3
and claudin-5 mRNA was increased, with increased clau-
din-5 expression also being confirmed by immunofluores-
cence. Reduced VE-cadherin expression in an AD mouse
model and in postmortem tissue of AD patients has been
reported (Lee et al., 2018). VE-cadherin is a key component
of adherens junctions and its loss increases vascular perme-
ability (Lee et al., 2018; Zenaro et al., 2017). In contrast,
claudin-3 and claudin-5 are both key barrier-forming clau-
dins (Gunzel and Yu, 2013); thus, their reduced expression
in AD could cause observed reduction in BBB integrity.
Interestingly, claudin-3 may not be expressed in BBB endo-
thelial cells in mice (Castro Dias et al., 2019), although
there are species differences between mice and human
BBBs (O’Brown et al., 2018), and claudin-3 is expressed in
human immortalized BECs (Schrade et al., 2012). There-
fore, it is possible that claudin-3 may have other important
functions in BECs.
Postmortem brain analysis has revealed decreased clau-
din-5 expression (Keaney et al., 2015; Yamazaki et al.,Figure 6. FUS Downregulates TJP mRNA with Reduced Recovery o
Relative expression of mRNA for occludin, VE-cadherin, claudin-5, an
after US + MB treatment (0.3 MPa) shown as fold change to isogenic
with two isogenic pairs). Data are presented as mean ± SEM. Statistic
0.01, ***p < 0.001, ****p < 0.0001. Only relevant differences are sh2019); however, the opposite has also been reported (Ro-
manitan et al., 2010). Changes to claudin-5 and other
TJPs in AD may be driven by Ab (Chao et al., 2016; Lee
et al., 2018; Yamazaki et al., 2019). We observed that AD-
iBECs with a PSEN1 mutation expressed higher levels of
some TJPs compared with healthy iBECs. It is unclear
how these changeswould affect the BBB. Higher expression
could increase integrity but may have other outcomes, and
this is supported by the lower TEER reading in AD-iBECs.
Altered TJP expression can affect Ab clearance from the
brain. This was supported by downregulation of occludin
and claudin-5 in the Tg2576 AD mouse model resulting
in increased Ab clearance (Keaney et al., 2015). Scanning
ultrasound treatment of the APP23 AD mouse model led
to transient opening of the BBB, but enhanced Ab clearance
was mediated via microglia rather than increased clearance
to blood (Leinenga and Go¨tz, 2015). In these mice, cogni-
tion was restored to wild-type levels. It remains to be deter-
mined how AD-iBECs would respond on Ab after ultra-
sound treatment if microglia were added to the system.f AD-iBECs mRNA Levels
d ZO-1 in isogenic COR- and AD-iBECs (A) immediately and (B) 24 h
COR-iBEC UT condition (n = 9 from three independent experiments
al analysis was performed using two-way ANOVA, *p < 0.05, **p <
own.
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Our findings may also have implications for cerebral amy-
loid angiopathy (CAA), which is a common characteristic
of AD (Andreas Charidimou et al., 2017). CAA can result
from, as well as, exacerbate AD-related BBB dysfunction.
Brain microvessels isolated from transgenic mouse models
of AD and CAA reveal increased BBB leakage, and altered
expression of TJPs (Magaki, et al., 2018). More recently it
has been shown in aged APP23 mice that ultrasound treat-
ment did not cause increased CAA or microbleeds, but
cleared interstitial Ab effectively (Leinenga and Go¨tz,
2018). Further studies are needed to determine if the
PSEN1-mediated changes to iBEC integrity and TJP expres-
sion modulate or are affected by CAA.
In our study, Ab generation by iBECs was not measured.
Although endothelial cells have the capacity to generate Ab
(Placido et al., 2015), there is little understanding of how
PSEN1 mutations affect Ab turnover in this cell type. It is
not known whether increased Ab, or an alternative role
for the PSEN1 mutation in the AD-iBECs, led to the
observed changes in some TJP expression compared with
healthy ctrl-iBECs. There are no reports of direct processing
of TJPs by presenilin 1; however, presenilin 1 modulates
Notch signaling via the g-secretase complex (De Strooper
et al., 1999). Notch signaling can alter BBB permeability
through effects on TJPs (Ma et al., 2017). The specificity
of these affects for AD-iBECs from patients with PSEN1mu-
tations should be further investigated by comparison with
iBECs generated from patients with alternative PSEN and
APP mutations, and ApoE isoforms.
We also identified differences in transporter expression
in AD-iBECs, implying altered transport across the BBB in
AD. Reduced GLUT-1 expression occurs in AD patients
and animal models (Hooijmans et al., 2007; Vogelsang
et al., 2018); however, we did not identify differences be-
tween AD- and combined ctrl-iBECs. We did find reduced
expression and function of the efflux transporter P-gp in
AD-iBECs, supporting previous findings in AD mouse
models and human patients. Decreased P-gp expression
correlates with increased Ab accumulation in mouse
models of AD (Vogelgesang et al., 2002; Wang et al.,
2016) and imaging of brains of patients with mild AD
demonstrated reduced P-gp activity compared with con-
trols (Deo et al., 2014). This evidence supports a role for
P-gp in Ab clearance from the brain, and our identified
reduced P-gp expression in AD-iBECs supports a likely
contribution of the altered P-gp to AD pathogenesis.
MRP1, MRP2, and BCRP efflux transporters were also
increased in AD-iBECs compared with controls. The trans-
porters belong to the family of ATP-cassette (ABC) trans-
porters that play a major role in inhibiting the entry of
drugs into the CNS (Qosa et al., 2015). Interestingly, Xiong
et al. (2009) reported an upregulation of BCRP in the brains
of AD patients, supporting our findings. Both P-gp and936 Stem Cell Reports j Vol. 14 j 924–939 j May 12, 2020BCRP are suggested to play a role in Ab transport across
the BBB (Tai et al., 2009), suggesting the altered expression
of these efflux transporters could contribute to abnormal
Ab homeostasis in the brain. In addition, oxidative stress
has been shown to increase ABC transporter expression at
the BBB, hypothesized to be required to remove detoxifica-
tion products (Wang et al., 2014). With oxidative stress
associated with AD progression, it could explain increased
efflux transporter expression in our model (Chen et al.,
2012). More functional analyses of the role of transporter
activity in BECs is important to understand the conse-
quences on AD progression and drug delivery.
FUS has shown promising effects in tau-specific antibody
delivery into the brain as well as in reducing Ab plaque and
tau load in mouse models of AD (Leinenga and Go¨tz, 2015;
Nisbet et al., 2017; Pandit et al., 2019b). In addition, ultra-
sound treatment was safe in a number of animal models
(Baseri et al., 2010; Blackmore et al., 2018; Leinenga et al.,
2016). Therefore, FUS combined with MBs is a promising
method for more efficient drug delivery across the BBB.
As the effects of FUS in a human disease-specific BBBmodel
remain sparsely investigated, we examined effects of FUS in
our human model. We demonstrate for the first time the
ability of FUS with MBs to disrupt an iBEC monolayer
with recovery 24 h after treatment. The effects of FUS +
MB treatment were clearly different onmonolayer opening
and permeability in AD- compared with isogenic COR-
iBECs. Unexpectedly, our data suggest that the AD-iBEC
monolayer is more resilient to immediate effects of FUS,
but recovers more slowly from treatment compared with
isogenic COR-iBECs. The resistance demonstrated by AD-
iBECs to FUS treatment could be due to increased claudin
expression as discussed above.
We also show that US + MB increased permeability of
iBEC monolayers to 3–5-kDa sized dextrans and Ab.
Although the compounds were added to the apical side,
corresponding to the blood side in the body, Ab flux across
the BBB is reported to be bidirectional (Wang et al., 2016),
suggesting that FUS has a potential to clear Ab also from the
basolateral side. Importantly, 24 h after FUS treatment
permeability to dextrans and Ab remained high in AD-
iBECs while it recovered in isogenic COR-iBECs. The trans-
port of larger molecules has not been explored by us.
Within the limitation of our study that assessed a particular
familial mutation of AD, in a clinical setting, an advantage
could be a more efficient clearance of Ab from AD brains or
the more efficient delivery of therapeutic drugs. This high-
lights the importance of investigating disease-specific ef-
fects of FUS on the BBB, but also asks for validation in an
in vivo model to integrate findings made in in vitro and
in vivo systems. A recent trial proved safety of FUS-mediated
BBB opening in five patients with early to moderate AD
(Lipsman et al., 2018), and a second trial showed that
even implanted transducers were tolerated in patients with
glioblastomas, without inducing neurotoxicity (Idbaih
et al., 2019). With FUS shown to induce Ab internalization
by microglia (Leinenga and Go¨tz, 2015), in future studies a
human in vitro model that comprises key BBB and brain
cells, including BECs, pericytes, astrocytes and microglia,
would be useful.
In conclusion, our results demonstrate that PSEN1
mutant AD-iBECs harbor phenotypical differences eluci-
dating disease-specific effects on the BBB in AD. In
addition, we show that these cells provide an excellent
complementary model to investigate new means of drug
delivery and to understand how the BBB can be exploited
for the treatment of AD.EXPERIMENTAL PROCEDURES
hiPSC Expansion and iBEC Differentiation
Six hiPSC lines were used, including three FAD lines harboring
the PSEN1 exon 9 deletion (Oksanen et al., 2017), two correspond-
ing isogenic gene-corrected controls lines (Oksanen et al., 2017),
and one unrelated healthy control line HDFa reprogrammed
from adult dermal fibroblasts (HDFa, Gibco, C0135C) using the
CytoTune-iPS 2.0 Sendai Reprogramming Kit (Invitrogen,
A16518). Details of the HDFa line generation are provided in Sup-
plemental Experimental Procedures. All hiPSC lines were main-
tained on human recombinant vitronectin in StemFlex medium
(Life Technologies). Differentiation was performed as described
previously (Qian et al., 2017; Stebbins et al., 2016) with some
modification, and is described in detail in Supplemental Experi-
mental Procedures. Theworkwas approved by theQIMRBerghofer
Human Ethics Committee.FUS
FUS experiments were performed on two AD and two respective
isogenic (corrected) control lines. The effect of ultrasound was
tested on iBECs 48–72 h after subculture. For immunofluorescent
detection, cells were grown on 24-well plates, and for TEER and
permeability assays cells were grown on Transwell inserts. Two
time points were used (immediately and 24 h after ultrasound)
and cells were tested under four conditions: (1) UT, (2) MB control,
(3) US control, and (4) test condition (US + MB), which received
both ultrasound and MBs. MBs were prepared as described previ-
ously (Leinenga and Go¨tz, 2015) and added to the wells aseptically
(10 mL per well). Cells were then exposed to the ultrasound trans-
ducer (Sonic Concepts H117) using the following parameters: 0.3
or 0.15 MPa peak rarefactional pressure, 50 cycles/burst, burst
period 20 ms, 286 Hz center frequency, and a 120-s sonication
time. For the US condition, cells were sonicated at the same param-
eters without MBs. For the MB condition, MBs were added to the
individual wells for 120 s and no ultrasound was performed.Dextran and Ab Leakage Analysis
To examine the barrier integrity of the iBECmonolayer after ultra-
sound treatment, the permeability to fluorescein isothiocyanate(FITC)-conjugated dextran molecules of 3–5 kDa (Sigma) and
FITC-conjugated Ab42 (Bachem) in Transwell inserts was analyzed.
For dextran leakage, after ultrasound exposure, the top chamber
medium was removed and replaced with medium containing
0.5 mg/mL of dextrans. For the 0-h time point, dextrans were
added on inserts immediately after ultrasound and bottom cham-
bermedium collected for analysis after 30min. Culturemedium in
both top and bottom chambers was then replaced with fresh me-
dium and after 24 h recovery dextrans were added again to the
top chamber and incubated for 30 min as in the immediate time
point. To examine leakage of Ab through the iBECmonolayer after
ultrasound treatment, top chamber medium was removed and re-
placed with culture medium containing 5 mM of FITC-Ab. Cells
were incubatedwith FITC-Ab for 24 h, after which the top and bot-
tom chamber media were collected for analysis. Fluorescence of
both dextrans and Ab was measured using a fluorescent plate
reader (Biotek Synergy H4) at 490 nm excitation/520 nm emission
wavelengths. For analysis of Ab leakage, the ratio of bottom/top
chamber fluorescence was calculated.Statistical Analysis
Statistical analysis was performed with GraphPad Prism 7.02 using
Student’s t test, one-way ANOVA with Tukey’s multiple compari-
son test, or two-way ANOVA with Sidak’s multiple comparison
test. Statistical significance was determined as *p < 0.05, **p <
0.01, ***p < 0.001, ****p < 0.0001. All data are presented as
mean ± SEM.SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/
10.1016/j.stemcr.2020.03.011.
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